JustInvest LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,372 shares of the company’s stock after buying an additional 1,458 shares during the quarter. JustInvest LLC’s holdings in Eli Lilly and were worth $1,683,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. FMR LLC raised its position in Eli Lilly and by 7.0% during the second quarter. FMR LLC now owns 29,992,097 shares of the company’s stock worth $4,924,101,000 after acquiring an additional 1,954,811 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Eli Lilly and by 7.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 9,044,905 shares of the company’s stock valued at $1,484,993,000 after buying an additional 629,683 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in Eli Lilly and by 42.0% during the 2nd quarter. Nuveen Asset Management LLC now owns 8,026,867 shares of the company’s stock valued at $1,317,851,000 after buying an additional 2,372,251 shares during the last quarter. Fisher Asset Management LLC increased its position in Eli Lilly and by 3.8% during the second quarter. Fisher Asset Management LLC now owns 4,498,977 shares of the company’s stock worth $738,642,000 after buying an additional 164,530 shares in the last quarter. Finally, California Public Employees Retirement System raised its holdings in shares of Eli Lilly and by 6.2% in the second quarter. California Public Employees Retirement System now owns 4,190,141 shares of the company’s stock worth $687,937,000 after acquiring an additional 245,800 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

A number of research firms recently commented on LLY. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Berenberg Bank began coverage on shares of Eli Lilly and in a report on Tuesday, September 29th. They set a “hold” rating and a $144.00 price target for the company. Truist started coverage on shares of Eli Lilly and in a research note on Friday, October 23rd. They issued a “buy” rating and a $180.00 target price for the company. ValuEngine lowered Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Morgan Stanley lowered their price objective on Eli Lilly and from $176.00 to $170.00 and set an “overweight” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $169.93.

In other Eli Lilly and news, SVP Melissa S. Barnes sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $151.01, for a total transaction of $755,050.00. Following the transaction, the senior vice president now owns 23,580 shares in the company, valued at $3,560,815.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.09% of the company’s stock.

Shares of Eli Lilly and stock traded up $0.54 during trading hours on Wednesday, reaching $132.44. The stock had a trading volume of 201,653 shares, compared to its average volume of 3,891,860. The firm has a market capitalization of $126.16 billion, a price-to-earnings ratio of 21.44, a P/E/G ratio of 1.25 and a beta of 0.19. Eli Lilly and Company has a 1 year low of $110.51 and a 1 year high of $170.75. The company has a current ratio of 1.22, a quick ratio of 0.94 and a debt-to-equity ratio of 3.53. The firm has a 50 day simple moving average of $148.41 and a two-hundred day simple moving average of $153.60.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $1.54 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.71 by ($0.17). Eli Lilly and had a net margin of 24.48% and a return on equity of 183.80%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.87 billion. During the same quarter in the previous year, the business posted $1.48 EPS. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Sell-side analysts forecast that Eli Lilly and Company will post 7.28 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $0.74 dividend. The ex-dividend date is Thursday, November 12th. This represents a $2.96 annualized dividend and a yield of 2.23%. Eli Lilly and’s dividend payout ratio is currently 49.01%.

Eli Lilly and Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.

See Also: What is required to own or exchange cryptocurrency?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.